Healthcare Triangle Enters Neurotechnology AI Devices and Solutions for Southeast Asia

The initiative targets device sales, professional training and recurring clinic software subscriptions, with Malaysian assembly planned.

Rhea-AI Summary

Healthcare Triangle (HCTI) launched Neurotechnology AI Devices Sales and Solutions through its wholly owned subsidiary Quantum Nexis, initially targeting Malaysia and Indonesia.

The initiative combines devices, professional education and AI-supported clinical software. Its three planned revenue streams are device sales and servicing, academy training and certification, and recurring software subscriptions for clinics.

The company targets its first submission to Malaysia's Medical Device Authority in Q1 2027 and first locally assembled devices in Q3 2027. Its manufacturing roadmap covers phased integration and assembly in Malaysia. Manufacturing and market introduction depend on technical agreements, quality requirements and applicable regulatory authorisations. AI-supported outputs require validation, sensitive-information protection and assessment for local populations.

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.Quantum Nexis plans three revenue streams: devices and servicing, training and certification, and recurring clinic software subscriptions.
• Minor point. Forward-looking: it has not happened yet and may not happen.Malaysian manufacturing plans target first locally assembled devices in Q3 2027.

Negative

• Minor pointManufacturing and market introduction depend on technical agreements, quality requirements and applicable regulatory authorisations.
• Minor pointAI-supported outputs require validation, sensitive-information protection and local-population suitability assessment.

Key Figures

Launch-market population: More than 310 million people Asia-Pacific mental health technology growth: 13.2% annually Revenue streams: 3 +2 more

Launch-market population

More than 310 million people

Malaysia and Indonesia, the initiative's initial focus

Asia-Pacific mental health technology growth

13.2% annually

Projected through 2030

Revenue streams

3

Device sales and servicing, professional training, and AI-enabled software subscriptions

First regulatory submission

Q1 2027

Planned submission to Malaysia's Medical Device Authority

First locally assembled devices

Q3 2027

Planned milestone in Malaysia

Key Terms

electroencephalography, quantitative eeg (qeeg), neurofeedback, transcranial electrical stimulation, +1 more

5 terms

electroencephalography medical

"EEG and quantitative EEG (qEEG) tools for recording and analysing brain electrical activity"

Electroencephalography is a medical test that uses small sensors on the scalp to record the brain’s electrical activity over time, like an EKG for the brain. Investors care because EEG data can be used in drug and device development, patient diagnosis, and monitoring treatment effects; strong EEG results can influence clinical success, regulatory approvals, and market adoption, affecting a company’s value and risk profile.

quantitative eeg (qeeg) medical

"EEG and quantitative EEG (qEEG) tools for recording and analysing brain electrical activity"

Quantitative EEG (qEEG) is the computerized analysis of electroencephalogram (EEG) recordings that turns raw brain-wave signals into numerical measures and visual maps. It applies signal-processing techniques—such as spectral (frequency) analysis, power and coherence calculations, and comparisons against age-matched normative databases—to highlight patterns, deviations or changes over time; it supplements but does not replace clinical interpretation of the underlying EEG and must be interpreted alongside clinical information and raw EEG traces.

neurofeedback medical

"neurofeedback and physiological biofeedback systems"

A form of biofeedback that measures a person’s real-time brain activity (most commonly with an electroencephalogram, EEG) and presents that information as visual or auditory signals so the person can learn to change their own brain patterns. It is a non-invasive training technique used in clinical and wellness settings to encourage self-regulation of neural activity; its effects arise from repeated practice and feedback rather than from direct brain stimulation.

transcranial electrical stimulation medical

"non-invasive brain stimulation technologies, including transcranial electrical stimulation"

A noninvasive neuromodulation technique that applies low-level electrical currents to the head through electrodes placed on the scalp to alter brain activity. Different modes include transcranial direct current stimulation (tDCS), alternating current (tACS) and random noise stimulation (tRNS); each mode differs by waveform and intended physiological effect. The physiological impact depends on factors such as current intensity, electrode size and placement, stimulation duration, and treatment protocol, and devices marketed for medical or therapeutic use are subject to applicable regulatory requirements.

repetitive transcranial magnetic stimulation (rtms) medical

"repetitive transcranial magnetic stimulation (rTMS)"

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive medical procedure that uses a magnetized coil placed near the skull to deliver repeated, focused magnetic pulses that induce small electrical currents in targeted brain tissue and change neural activity. Treatments are given in repeated sessions with specific parameters (pulse frequency, intensity, train duration and target location) chosen to increase or decrease activity in particular brain regions; those parameters and the conditions approved by regulators vary by jurisdiction. Unlike surgical or electrical therapies that require anesthesia, rTMS does not penetrate the skull or directly open the brain, and its effects depend on the exact stimulation protocol and number of sessions administered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Malaysia and Indonesia, home to more than 310 million people with a fast-growing need for mental health care, form the initial focus of an initiative combining neuroscience devices, professional education and AI-supported mental healthcare

PLEASANTON, Calif., Oct. 26, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced the launch of Neurotechnology AI Devices Sales and Solutions through its wholly owned subsidiary, Quantum Nexis Inc. ("Quantum Nexis"), with strategic healthcare, wellness, neuroscience and public-sector initiatives being actively pursued across Southeast Asia.

As healthcare systems shift toward preventive care, mental resilience, longevity, cognitive performance and wellness outcomes, Quantum Nexis is building a strategic foundation to bring advanced brain mapping and neurotechnology capabilities to healthcare organisations, wellness centres, hospitality groups, enterprises and government-aligned initiatives throughout Malaysia and Indonesia.

The solutions bring together neurotechnology, neuropsychology, psychotherapy and AI through program encompassing device manufacturing development, clinical technology integration and professional education. The aim is to help practitioners translate advances in brain science into responsible, practical applications for mental health treatment, rehabilitation and cognitive wellbeing.

Key Highlights

• Large, fast-growing market: Malaysia and Indonesia are home to more than 310 million people. Asia-Pacific is the fastest-growing region for mental health technology, with a projected 13.2% annual growth rate from 2024 to 2030 (Ariston).
• Three revenue streams: Neurotechnology device sales and servicing; professional training and certification through a Quantum Nexis academy; and recurring AI-enabled software subscriptions for clinics.
• Builds on HCTI's core strengths: HCTI's existing cloud, data and AI capabilities power the clinical software layer.
• Local manufacturing base: Phased device integration and assembly in Malaysia, whose medical device exports grew 31% to RM37 billion in 2024.
• Near-term milestones: First regulatory submission to Malaysia's Medical Device Authority Q1 2027; first locally assembled devices Q3 2027.

The market opportunity

Demand for brain-health technology is accelerating worldwide. The global neurotech devices market is projected to grow from US$15.2 billion in 2024 to US$30.3 billion by 2030, a compound annual growth rate of 12.2% (Market Glass). Within mental health technology, Asia-Pacific is the fastest-growing region, at a projected 13.2% a year through 2030 (Ariston).

In the initiative's two launch markets, the need is pressing and the gap in care is wide:

• Malaysia: around one million people aged over 15, or 4.6% of that population, live with depression, double the number recorded in 2019, according to the Ministry of Health's National Health and Morbidity Survey (NHMS) 2023. The same survey found that about one in six children is likely to experience mental health problems.
• Indonesia: only 10.4% of young people aged 15 to 24 with depression seek treatment, according to the Ministry of Health's 2023 Indonesian Health Survey (SKI). The Ministry ranks mental health problems as the second-largest cause of years lived with disability in the country.

Together, these figures point to a large population that would benefit from better assessment, earlier intervention and more personalised care, and to the need for more professionals trained to deliver it.

"Making neurotechnology accessible requires more than supplying equipment. Professionals need the knowledge to interpret the information, select appropriate interventions and understand the limits of each technology," said Ehsan Masoumi, Director, Quantum Nexis. "Our vision is to develop regional capability across devices, software, education and clinical practice, so that advances in neuroscience can contribute meaningfully to people's mental health and everyday functioning."

Building regional technology and manufacturing capability

The development roadmap includes EEG and quantitative EEG (qEEG) tools for recording and analysing brain electrical activity; neurofeedback and physiological biofeedback systems; and non-invasive brain stimulation technologies, including transcranial electrical stimulation and repetitive transcranial magnetic stimulation (rTMS).

A core strategic objective is to develop manufacturing capability in Malaysia through a phased pathway covering device integration, assembly, software configuration, testing, calibration, quality assurance and technical support.

Manufacturing and market introduction will progress in accordance with technical agreements, quality requirements and applicable regulatory authorisations.

Connecting neuroscience with artificial intelligence

AI development will focus on helping professionals organise and interpret complex information across clinical assessments, cognitive measures, physiological recordings and treatment progress.

Potential applications include assisting with signal quality review, identifying patterns for further clinical investigation, supporting documentation and tracking changes over time. As these capabilities are validated, they could help practitioners make better-informed decisions and evaluate whether an intervention is delivering meaningful benefit.

Clinical judgment, patient consent and professional accountability will remain central. AI-supported outputs will require appropriate validation, protection of sensitive information and assessment of their suitability for local populations.

About Healthcare Triangle

Healthcare Triangle, Inc. (Nasdaq: HCTI) provides digital transformation, AI and cloud-related services to healthcare and other enterprise customers through its operating businesses.

About QuantumNexis

QuantumNexis, a subsidiary of Healthcare Triangle, is dedicated to advancing digital mental health solutions that are clinically validated, accessible, and culturally sensitive. Quantum Nexis's digital health ecosystem focused on AI‑powered platforms, interoperability, and healthcare modernization. Through its multi‑brand portfolio and strategic partnerships, the company supports hospitals, clinics, and health systems across Asia, the Middle East, Africa, and Europe. For more information, please visit www.quantumnexis.ai 

Forward-Looking Statements

This release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning the expected start, ramp-up, scope, performance and revenue of HCTI's and QuantumNexis engagements; the possible signing and targeted economics of an additional unsigned engagement; potential combined annual run-rate amounts; HCTI's customer relationships, advisory work, product development, deployment, commercial adoption and future growth; and anticipated market opportunities. Forward-looking statements are based on current management assumptions and involve substantial risks and uncertainties. Signed engagements may be delayed, amended, reduced, terminated or perform below expectations; actual client volumes, currency exchange rates and revenue recognition may differ materially from estimates. The estimated unsigned-opportunity target are not revenue guidance for any fiscal period and should not be interpreted as guaranteed or contracted revenue. AI offerings may not achieve expected adoption or commercial results. Actual outcomes may differ materially due to these and other risks, including those discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Market and industry data in this release are drawn from third-party and government sources, including Market Glass, Inc., the Malaysian Ministry of Health (NHMS 2023), the Indonesian Ministry of Health (SKI 2023) and the Malaysian Investment Development Authority. The Company has not independently verified this data.

Investor Relations

Healthcare Triangle, Inc. | 1-800-617-9550 | ir@healthcaretriangle.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-triangle-enters-neurotechnology-ai-devices-and-solutions-for-southeast-asia-302919003.html

SOURCE Healthcare Triangle, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What business is Healthcare Triangle launching through Quantum Nexis?

Healthcare Triangle is launching Neurotechnology AI Devices Sales and Solutions through Quantum Nexis, initially focusing on Malaysia and Indonesia. The initiative combines neurotechnology devices, professional education and AI-supported clinical software, with planned revenue from device sales and servicing, training and certification, and recurring clinic software subscriptions.

What are Healthcare Triangle's milestones for its Malaysian neurotechnology initiative?

The company targets its first submission to Malaysia's Medical Device Authority in Q1 2027 and first locally assembled devices in Q3 2027. Manufacturing and market introduction will proceed in accordance with technical agreements, quality requirements and applicable regulatory authorisations.